Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Vascepa
Pharma
Amarin sells Vascepa's rights in Europe to Recordati for $25M
Amarin has forged a potentially $175 million deal with Recordati to commercialize Vascepa in Europe.
Kevin Dunleavy
Jun 24, 2025 11:26am
Investor group calls for strategy shift at struggling Amarin
Mar 20, 2025 11:00am
Amarin, after stock crash and layoffs, revives patent lawsuit
Jun 26, 2024 1:01pm
Amarin's CEO resigns, leaving former interim chief to take over
Jun 4, 2024 11:19am
Teva, like Hikma, accuses Amarin of hoarding Vascepa ingredient
Mar 29, 2024 1:10pm
Amarin axes 120 of its 385 employees, hires new CEO Patrick Holt
Jul 19, 2023 10:45am
